Last update Aug. 24, 2022

Eptacog Alfa (Activated); recombinant factor VIIa

Compatible

Safe product and/or breastfeeding is the best option.

Factor VII is a vitamin K-dependent plasma glycoprotein consisting of 406 amino acids. It is involved in blood coagulation. It can be obtained from human plasma or produced by recombinant DNA technology (Eptacog Alfa). It is used to treat bleeding disorders such as hemophilia, Glanzmann's thrombasthenia, and congenital factor VII deficiency, and in the treatment of severe postpartum hemorrhage unresponsive to uterotonics. Intravenous administration.

Since the last update we have not found published data on its excretion in breastmilk.

Its very high molecular weigh and its binding to coagulation factors X and IX and tissue factor make it highly unlikely that significant quantities will pass into breast milk.

Due to its protein nature, it is inactivated in the gastrointestinal tract, and is not absorbed, (it has virtually no oral bioavailability), which hinders or prevents its transfer from breastmilk to infant, except in premature babies and the immediate neonatal period, when there may be greater intestinal permeability.

Expert authors consider the use of this medication probably compatible during breastfeeding. (Hale). Recommendations for Drugs in the Eleventh WHO Model List of Essential Drugs: compatible with Breastfeeding. (WHO 2002)

Alternatives

We do not have alternatives for Eptacog Alfa (Activated); recombinant factor VIIa since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Eptacog Alfa (Activated); recombinant factor VIIa is also known as Coagulation factor VII. Here it is a list of alternative known names::


Eptacog Alfa (Activated); recombinant factor VIIa in other languages or writings:

Group

Eptacog Alfa (Activated); recombinant factor VIIa belongs to this group or family:

Tradenames

Main tradenames from several countries containing Eptacog Alfa (Activated); recombinant factor VIIa in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 0 %
Molecular weight 50.000 daltons
VD 0.002 l/Kg
3 - 6 hours

References

  1. Hale TW. Medications & Mothers' Milk. 1991- . Springer Publishing Company. Available from https://www.halesmeds.com Consulted on April 10, 2024 Full text (link to original source)
  2. Novo Nordisk. Eptacog. Drug Summary. 2018 Full text (in our servers)
  3. EMA. Eptacog. Ficha técnica. 2006 Full text (in our servers)
  4. WHO / UNICEF. BREASTFEEDING AND MATERNAL MEDICATION Recommendations for Drugs in the Eleventh WHO Model List of Essential Drugs. Department of Child and Adolescent Health and Development (WHO/UNICEF) 2002 Abstract Full text (link to original source) Full text (in our servers)

Total visits

898

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by IHAN of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM